Daxxify (Daxibotulinumtoxin-A)
Daxxify; Botulinum toxin type A product, developed by Revance Therapeutics, containing a peptide stimulator (RTP-004) and approved by the FDA for cosmetic indication in 2022, used in the treatment of glabellar wrinkles; It is a longer-acting alternative to Botox, with an effect duration of up to 6 months.